Medizone International Expands Patent Coverage for AsepticSure

AsepticSure receives US Patent for Food-Handling Facility Disinfectant


June 20, 2017 – Medizone International, Inc. (OTCQB: MZEI) (Kalamazoo, MI) today announces the United States Patent and Trademark Office has agreed to grant a patent for Food-Handling Facility Disinfectant for AsepticSure (US Patent 9,616,144).

“Our team our researchers continues to demonstrate the broad utility of AsepticSure in a number of commercial applications,” commented David A. Esposito, Chairman of the Board and interim CEO of Medizone International. “The granting of this patent helps to strengthen our intellectual property to ensure protected access to these large market opportunities.”

The food services industry is a significant market opportunity for the Company. The patent for Food-Handling Facility Disinfectant adds to a strong portfolio of IP covering hospital disinfection, bioterrorism counter measures, and sports equipment and facility disinfection.

About Medizone International, Inc.

Founded initially in 1986 to develop treatments for lipid-enveloped viruses, Medizone International, Inc. shifted focus in 2007 to develop a superior disinfectant technology. The company developed the AsepticSure system to combine oxidative compounds (O3 and H202) to produce a unique mixture of free radicals (H2O3 known as trioxidane) with much higher oxidative potential than ozone or hydrogen peroxide alone. After securing broad IP protection for the use of trioxidane for both healthcare facility disinfecting systems and bioterrorism applications, the company released its AsepticSure system for use in Canada, and several other global markets.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. Our actual results could differ materially from those projected in these forward-looking statements, which involve a number of risks and uncertainties, including the risk that government and international agencies and organizations may not adopt our system, global economic conditions generally, government regulation, manufacturing and marketing risks, adverse publicity risks, risks associated with our entry into the U.S. and other markets, expansion and operations. The contents of this release should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in our most recent filings with the Securities and Exchange Commission.

For press information on Medizone International, please contact:
John Pentony, Investor and Media Relations
Medizone International, Inc.
T: 01 269-202-5020
E: [email protected]

For more information, visit:
Email: [email protected]

Medizone International, Inc. (OTCQB: MZEI)

350 East Michigan Avenue – Suite 500
Kalamazoo, MI 49007

Telephone: (269) 202-5020

Email: [email protected]

Media and Investor Relations:

John Pentony

Medizone International, Inc.

Telephone: (269) 202-5020

Email: [email protected]

Social Media